MarketBeat
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead
📈
AI Sentiment
Highly Positive
9/10
Annexon Inc. News
Latest updates and market news for ANNX
2 news
Jan 10 - Jan 16, 2026
Page 1
GlobeNewswire
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
📈
AI Sentiment
Highly Positive
9/10
Share this news page